Effect of dulaglutide on liver fat in patients with type 2 diabetes and NAFLD: randomised controlled trial (D-LIFT trial).

Kuchay MS, Krishan S, Mishra SK, Choudhary NS, Singh MK, Wasir JS, Kaur P, Gill HK, Bano T, Farooqui KJ, Mithal A

Diabetologia31 Aug 2020Cited by 201 (Europe PMC)

PMID32865597DOI10.1007/s00125-020-05265-7PepBankPUB-32865597

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanRandomized controlled trialEfficacy outcome
In adults with diabetes and NAFLD, dulaglutide reduced liver fat versus usual care.
In plain wordsIn adults with diabetes and fatty liver, dulaglutide reduced liver fat more than usual care.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseLiver fat content
Study
n = 52
Comparator
Usual care
Analysis
Primary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
Absolute LFC difference
−3.5%
versus usual care
Relative LFC difference
−26.4%
versus usual care
Fold greater reduction in LFC
2.6 fold
versus usual care
95% confidence interval of difference
−6.6 to −0.4%
reported treatment comparison
95% confidence interval of relative LFC difference
−44.2 to −8.6%
versus usual care
Source sentences
Summary
Dulaglutide treatment resulted in a control-corrected absolute change in LFC of -3.5% (95% CI -6.6, -0.4; p = 0.025) and relative change of -26.4% (-44.2, -8.6; p = 0.004), corresponding to a 2.6-fold greater reduction.
2 context sentences(design, population, supporting numbers)
Summary · context
Effect of dulaglutide on liver fat (D-LIFT) was a 24 week, open-label, parallel-group, randomised controlled trial to determine the effect of dulaglutide on liver fat at a tertiary care centre in India.
Summary · context
Adults (n = 64), who had type 2 diabetes and MRI-derived proton density fat fraction-assessed LFC of ≥6.0% at baseline, were randomly assigned to receive dulaglutide weekly for 24 weeks (add-on to usual care) or usual care
Report a problemFND-3286559701
02HumanRandomized controlled trialEfficacy outcome
In adults with diabetes and NAFLD, dulaglutide reduced GGT versus usual care.
In plain wordsIn adults with diabetes and fatty liver, dulaglutide reduced GGT more than usual care.
Peptide
Dulaglutide (Trulicity)
Outcome
DecreaseGGT
Study
n = 52
Comparator
Usual care
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
GGT difference
−13.1 U/l
versus usual care
Source sentences
Summary
Dulaglutide-treated participants also showed a significant reduction in γ-glutamyl transpeptidase (GGT) levels (mean between-group difference -13.1 U/l [95% CI -24.4, -1.8]; p = 0.025)
2 context sentences(design, population, supporting numbers)
Summary · context
Effect of dulaglutide on liver fat (D-LIFT) was a 24 week, open-label, parallel-group, randomised controlled trial to determine the effect of dulaglutide on liver fat at a tertiary care centre in India.
Summary · context
Adults (n = 64), who had type 2 diabetes and MRI-derived proton density fat fraction-assessed LFC of ≥6.0% at baseline, were randomly assigned to receive dulaglutide weekly for 24 weeks (add-on to usual care) or usual care
Report a problemFND-3286559702
03HumanRandomized controlled trialEfficacy outcome
In adults with diabetes and NAFLD, dulaglutide did not significantly reduce AST versus usual care.
In plain wordsIn adults with diabetes and fatty liver, AST did not differ significantly between dulaglutide and usual care.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeAST
Study
n = 52
Comparator
Usual care
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
AST difference
−9.3 U/l
versus usual care
95% confidence interval of difference
−19.5 to 1 U/l
reported treatment comparison
Source sentences
Summary
and non-significant reductions in aspartate aminotransferase (AST) (-9.3 U/l [-19.5, 1.0]; p = 0.075)
2 context sentences(design, population, supporting numbers)
Summary · context
Effect of dulaglutide on liver fat (D-LIFT) was a 24 week, open-label, parallel-group, randomised controlled trial to determine the effect of dulaglutide on liver fat at a tertiary care centre in India.
Summary · context
Adults (n = 64), who had type 2 diabetes and MRI-derived proton density fat fraction-assessed LFC of ≥6.0% at baseline, were randomly assigned to receive dulaglutide weekly for 24 weeks (add-on to usual care) or usual care
Report a problemFND-3286559703
04HumanRandomized controlled trialEfficacy outcome
In adults with diabetes and NAFLD, dulaglutide did not significantly reduce ALT versus usual care.
In plain wordsIn adults with diabetes and fatty liver, ALT did not differ significantly between dulaglutide and usual care.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeALT
Study
n = 52
Comparator
Usual care
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
ALT difference
−13.1 U/l
versus usual care
95% confidence interval of difference
−24.4 to 2.5 U/l
reported treatment comparison
Source sentences
Summary
and non-significant reductions in aspartate aminotransferase (AST) (-9.3 U/l [-19.5, 1.0]; p = 0.075) and alanine aminotransferase (ALT) levels (-13.1 U/l [-24.4, 2.5]; p = 0.10).
2 context sentences(design, population, supporting numbers)
Summary · context
Effect of dulaglutide on liver fat (D-LIFT) was a 24 week, open-label, parallel-group, randomised controlled trial to determine the effect of dulaglutide on liver fat at a tertiary care centre in India.
Summary · context
Adults (n = 64), who had type 2 diabetes and MRI-derived proton density fat fraction-assessed LFC of ≥6.0% at baseline, were randomly assigned to receive dulaglutide weekly for 24 weeks (add-on to usual care) or usual care
Report a problemFND-3286559704
05HumanRandomized controlled trialEfficacy outcome
In adults with diabetes and NAFLD, pancreatic fat did not differ significantly between dulaglutide and usual care.
In plain wordsIn adults with diabetes and fatty liver, pancreatic fat did not differ significantly between dulaglutide and usual care.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changePancreatic fat content
Study
n = 52
Comparator
Usual care
Analysis
Secondary
Outcome group
Body composition · Metabolic and weight
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
Pancreatic fat content absolute change difference
−1.4%
versus usual care
95% confidence interval of difference
−3.2 to 0.3%
reported treatment comparison
Source sentences
Summary
Absolute changes in PFC (-1.4% [-3.2, 0.3]; p = 0.106) and LSM (-1.31 kPa [-2.99, 0.37]; p = 0.123) were not significant when comparing the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Effect of dulaglutide on liver fat (D-LIFT) was a 24 week, open-label, parallel-group, randomised controlled trial to determine the effect of dulaglutide on liver fat at a tertiary care centre in India.
Summary · context
Adults (n = 64), who had type 2 diabetes and MRI-derived proton density fat fraction-assessed LFC of ≥6.0% at baseline, were randomly assigned to receive dulaglutide weekly for 24 weeks (add-on to usual care) or usual care
Report a problemFND-3286559705
06HumanRandomized controlled trialEfficacy outcome
In adults with diabetes and NAFLD, liver stiffness did not differ significantly between dulaglutide and usual care.
In plain wordsIn adults with diabetes and fatty liver, liver stiffness did not differ significantly between dulaglutide and usual care.
Peptide
Dulaglutide (Trulicity)
Outcome
No significant changeLiver stiffness
Study
n = 52
Comparator
Usual care
Analysis
Secondary
Outcome group
Liver fat and liver function · Liver
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Measurements
Liver stiffness absolute change difference
−1.31 kPa
versus usual care
95% confidence interval of difference
−2.99 to 0.37 kPa
reported treatment comparison
Source sentences
Summary
Absolute changes in PFC (-1.4% [-3.2, 0.3]; p = 0.106) and LSM (-1.31 kPa [-2.99, 0.37]; p = 0.123) were not significant when comparing the two groups.
2 context sentences(design, population, supporting numbers)
Summary · context
Effect of dulaglutide on liver fat (D-LIFT) was a 24 week, open-label, parallel-group, randomised controlled trial to determine the effect of dulaglutide on liver fat at a tertiary care centre in India.
Summary · context
Adults (n = 64), who had type 2 diabetes and MRI-derived proton density fat fraction-assessed LFC of ≥6.0% at baseline, were randomly assigned to receive dulaglutide weekly for 24 weeks (add-on to usual care) or usual care
Report a problemFND-3286559706
07HumanRandomized controlled trialSafety outcome
In adults with diabetes and NAFLD, no serious drug-related adverse events occurred with dulaglutide.
In plain wordsIn adults with diabetes and fatty liver, no serious drug-related adverse events occurred with dulaglutide.
Peptide
Dulaglutide (Trulicity)
Outcome
Not applicableSerious drug-related adverse events
Study
n: not reported in source
Outcome group
Adverse events · Whole body
Studied dose
Dose not stated · 24 weeksAs given in this study (human).
Source sentences
Summary
There were no serious drug-related adverse events.
2 context sentences(design, population, supporting numbers)
Summary · context
Effect of dulaglutide on liver fat (D-LIFT) was a 24 week, open-label, parallel-group, randomised controlled trial to determine the effect of dulaglutide on liver fat at a tertiary care centre in India.
Summary · context
Adults (n = 64), who had type 2 diabetes and MRI-derived proton density fat fraction-assessed LFC of ≥6.0% at baseline, were randomly assigned to receive dulaglutide weekly for 24 weeks (add-on to usual care) or usual care
Report a problemFND-3286559707

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 completed · source ClinicalTrials.gov (opens in a new tab)

CompletedNot applicableNCT03590626

Effect of Dulaglutide on Liver Fat in Patients With Type 2 Diabetes and Nonalcoholic Fatty Liver Disease

Medanta, The Medicity, Indian = 601 Jan 2019 to 18 Feb 2020

Non Alcoholic Fatty Liver Disease · Type2 Diabetes Mellitus

Trial page ClinicalTrials.govUpdated 20 Feb 2020

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Versions 4 to 9Current
28 Oct 2026, 02:03 UTC
The same notice was added 6 times, first on 22 Oct 2026, 02:26 UTC. The status did not change between them.
Study results updated
Version 3
21 Oct 2026, 18:59 UTC
Study data updated · source update from Europe PMC
Version 2
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:05 UTC
First added · source update from Europe PMC